Soligenix Company Profile (NASDAQ:SNGX)

About Soligenix (NASDAQ:SNGX)

Soligenix logoSoligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:SNGX
  • CUSIP: N/A
  • Web: www.soligenix.com
Capitalization:
  • Market Cap: $11.85 million
  • Outstanding Shares: 5,723,000
Average Prices:
  • 50 Day Moving Avg: $2.27
  • 200 Day Moving Avg: $2.44
  • 52 Week Range: $2.02 - $14.40
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.41
  • P/E Growth: -1.47
Sales & Book Value:
  • Annual Revenue: $6.98 million
  • Price / Sales: 1.70
  • Book Value: $0.64 per share
  • Price / Book: 3.23
Profitability:
  • EBIDTA: ($6,760,000.00)
  • Net Margins: -86.15%
  • Return on Equity: -129.88%
  • Return on Assets: -74.33%
Debt:
  • Current Ratio: 2.11%
  • Quick Ratio: 3.19%
Misc:
  • Average Volume: 188,656 shs.
  • Beta: 2.31
  • Short Ratio: 4.96
 

Frequently Asked Questions for Soligenix (NASDAQ:SNGX)

What is Soligenix's stock symbol?

Soligenix trades on the NASDAQ under the ticker symbol "SNGX."

How were Soligenix's earnings last quarter?

Soligenix Inc. (NASDAQ:SNGX) announced its quarterly earnings data on Friday, August, 11th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by $0.09. The business earned $1 million during the quarter, compared to analyst estimates of $1.43 million. Soligenix had a negative net margin of 86.15% and a negative return on equity of 129.88%. View Soligenix's Earnings History.

When will Soligenix make its next earnings announcement?

Soligenix is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for Soligenix.

Where is Soligenix's stock going? Where will Soligenix's stock price be in 2017?

3 brokerages have issued 12-month target prices for Soligenix's stock. Their forecasts range from $5.00 to $11.00. On average, they expect Soligenix's stock price to reach $7.33 in the next twelve months. View Analyst Ratings for Soligenix.

Who are some of Soligenix's key competitors?

Who owns Soligenix stock?

Soligenix's stock is owned by many different of institutional and retail investors. Top institutional investors include KIRK RANDAL J (6.30%) and KIRK RANDAL J (4.90%). Company insiders that own Soligenix stock include Christopher J Schaber, Jerome B Zeldis, Marco Maria Brughera and Randal J Kirk. View Institutional Ownership Trends for Soligenix.

How do I buy Soligenix stock?

Shares of Soligenix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Soligenix's stock price today?

One share of Soligenix stock can currently be purchased for approximately $2.07.


MarketBeat Community Rating for Soligenix (NASDAQ SNGX)
Community Ranking:  3.8 out of 5 (  )
Outperform Votes:  69 (Vote Outperform)
Underperform Votes:  21 (Vote Underperform)
Total Votes:  90
MarketBeat's community ratings are surveys of what our community members think about Soligenix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Soligenix (NASDAQ:SNGX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.33 (254.27% upside)

Analysts' Ratings History for Soligenix (NASDAQ:SNGX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/14/2017HC WainwrightSet Price TargetBuy$11.00HighView Rating Details
8/14/2017Maxim GroupBoost Price TargetBuy -> Buy$4.00 -> $5.00HighView Rating Details
9/7/2016AegisInitiated CoverageBuy$6.00N/AView Rating Details
11/15/2015Brean CapitalReiterated RatingBuy$5.00N/AView Rating Details
(Data available from 8/18/2015 forward)

Earnings

Earnings History for Soligenix (NASDAQ:SNGX)
Earnings by Quarter for Soligenix (NASDAQ:SNGX)
Earnings History by Quarter for Soligenix (NASDAQ SNGX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017        
8/11/2017Q2 2017($0.32)($0.41)$1.43 million$1.00 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.30)($0.32)$1.30 millionViewN/AView Earnings Details
3/24/2016Q1($0.06)($0.04)$1.00 million$2.97 millionViewN/AView Earnings Details
8/12/2015($0.10)($0.15)$1.00 million$1.10 millionViewN/AView Earnings Details
3/24/2015($0.10)($0.07)$0.80 million$1.93 millionViewN/AView Earnings Details
11/10/2014($0.09)($0.08)$1.51 million$2.79 millionViewN/AView Earnings Details
8/11/2014($0.09)($0.05)$0.80 million$1.40 millionViewN/AView Earnings Details
5/12/2014($0.09)($0.08)$0.80 million$0.90 millionViewN/AView Earnings Details
3/26/2014($0.08)$0.13ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Soligenix (NASDAQ:SNGX)
Current Year EPS Consensus Estimate: $-1.48 EPS
Next Year EPS Consensus Estimate: $-1.47 EPS

Dividends

Dividend History for Soligenix (NASDAQ:SNGX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Soligenix (NASDAQ:SNGX)
Insider Ownership Percentage: 5.03%
Institutional Ownership Percentage: 8.77%
Insider Trades by Quarter for Soligenix (NASDAQ:SNGX)
Institutional Ownership by Quarter for Soligenix (NASDAQ:SNGX)
Insider Trades by Quarter for Soligenix (NASDAQ:SNGX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/8/2017Randal J KirkMajor ShareholderSell160,968$3.12$502,220.16View SEC Filing  
12/16/2016Christopher J SchaberCEOBuy15,804$3.16$49,940.64View SEC Filing  
12/16/2016Marco Maria BrugheraDirectorBuy2,000$3.16$6,320.00View SEC Filing  
12/23/2015Jerome B ZeldisDirectorBuy2,500$1.27$3,175.00View SEC Filing  
12/22/2015Christopher J SchaberCEOBuy10,000$1.29$12,900.00View SEC Filing  
12/22/2014Joseph Michael WaruszCFOBuy8,265$1.21$10,000.65View SEC Filing  
6/25/2013Christopher J SchaberCEOBuy9,523$1.05$9,999.15View SEC Filing  
6/25/2013Keith L BrownlieDirectorBuy19,047$1.05$19,999.35View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Soligenix (NASDAQ:SNGX)
Latest Headlines for Soligenix (NASDAQ:SNGX)
Source:
DateHeadline
americanbankingnews.com logoSoligenix Inc. (NASDAQ:SNGX) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 12 at 10:40 AM
americanbankingnews.com logo$1.43 Million in Sales Expected for Soligenix Inc. (SNGX) This Quarter
www.americanbankingnews.com - August 6 at 7:11 AM
americanbankingnews.com logo Brokerages Expect Soligenix Inc. (NASDAQ:SNGX) Will Announce Earnings of -$0.33 Per Share
www.americanbankingnews.com - August 4 at 6:26 PM
finance.yahoo.com logoSoligenix Begins Patient Enrollment for Pivotal Phase 3 Trial (SGX942) for Oral Mucositis & Enrollment in Phase III of SGX301 ongoing
finance.yahoo.com - August 2 at 4:38 PM
prnewswire.com logoTechnical Reports on Biotech Equities -- BioDelivery Sciences, BioLine Rx, Benitec Biopharma, and Soligenix
www.prnewswire.com - August 1 at 4:02 PM
americanbankingnews.com logoSoligenix Inc. (SNGX) PT Set at $11.00 by HC Wainwright
www.americanbankingnews.com - July 27 at 10:14 AM
nasdaq.com logoMid-Day Market Update: Sevcon Surges Following Acquisition News; TherapeuticsMD Shares Slide
www.nasdaq.com - July 19 at 1:47 AM
nasdaq.com logoMid-Morning Market Update: Markets Edge Higher; BlackRock Profit Misses Views
www.nasdaq.com - July 18 at 8:19 AM
americanbankingnews.com logoMaxim Group Reaffirms "Buy" Rating for Soligenix Inc. (SNGX)
www.americanbankingnews.com - June 19 at 1:32 PM
streetinsider.com logoSoligenix, Inc. (SNGX) tp Present Complete Efficacy & Long-Term Follow-Up Safety Results from SGX942 Phase 2 Oral Mucositis Clinical Trial
www.streetinsider.com - June 19 at 9:35 AM
finance.yahoo.com logoComplete Efficacy and Long-Term Follow-Up Safety Results from SGX942 Phase 2 Oral Mucositis Clinical Trial to be Presented at the 2017 Multinational Association for Supportive Care in Cancer Conference
finance.yahoo.com - June 19 at 9:35 AM
finance.yahoo.com logoWhat Biotech Offers a Better Risk/Reward Profile than Soligenix (SNGX)? In Our View, None
finance.yahoo.com - June 7 at 10:51 AM
americanbankingnews.com logoMaxim Group Analysts Give Soligenix, Inc. (SNGX) a $4.00 Price Target
www.americanbankingnews.com - May 23 at 6:58 PM
finance.yahoo.com logoSoligenix Announces Publication Of Its Phase 2 Long-term Follow-up Results Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients
finance.yahoo.com - May 18 at 1:03 PM
americanbankingnews.com logoSoligenix, Inc. (SNGX) PT Set at $4.00 by Maxim Group
www.americanbankingnews.com - May 13 at 6:26 PM
americanbankingnews.com logoSoligenix, Inc. (SNGX) Announces Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - May 12 at 12:38 PM
finance.yahoo.com logoWith Two Phase III Trials Operational & Significant Financial Leverage, Soligenix Shining
finance.yahoo.com - May 10 at 8:11 PM
finance.yahoo.com logoSoligenix Receives Japanese Patent for ThermoVax® Vaccine Heat Stabilization Platform Technology
finance.yahoo.com - May 9 at 10:25 AM
americanbankingnews.com logoRandal J. Kirk Sells 160,968 Shares of Soligenix, Inc. (SNGX) Stock
www.americanbankingnews.com - May 8 at 7:37 PM
americanbankingnews.com logoSoligenix, Inc. (SNGX) Given a $4.00 Price Target at Maxim Group
www.americanbankingnews.com - May 4 at 1:18 AM
streetinsider.com logoSoligenix, Inc. (SNGX) Announces FDA Protocol Clearance of Pivotal Phase 3 Trial of SGX942 to Treat Oral Mucositis in HNC
www.streetinsider.com - May 3 at 11:05 PM
rttnews.com logoSoligenix Inc. (SNGX) Has Surged To Over A 5-Month High
www.rttnews.com - April 20 at 12:53 AM
streetinsider.com logoSoligenix, Inc. (SNGX) Says Results from Ricin Toxin Vaccine Program to be Presented at Conference on Vaccine Research
www.streetinsider.com - April 20 at 12:53 AM
finance.yahoo.com logoEfficacy Results from Soligenix's Ricin Toxin Vaccine Program to be Presented at the 20th Annual Conference on Vaccine Research
finance.yahoo.com - April 19 at 9:13 AM
finance.yahoo.com logoSoligenix to Present at the World Orphan Drug Congress
finance.yahoo.com - April 12 at 1:01 PM
americanbankingnews.com logoFY2017 Earnings Forecast for Soligenix, Inc. Issued By Zacks Investment Research (SNGX)
www.americanbankingnews.com - March 31 at 12:47 PM
americanbankingnews.com logoAnalysts Set Expectations for Soligenix, Inc.'s FY2020 Earnings (SNGX)
www.americanbankingnews.com - March 30 at 1:52 PM
finance.yahoo.com logoSoligenix Announces Recent Accomplishments And Year-End 2016 Financial Results
finance.yahoo.com - March 27 at 9:07 AM
bizjournals.com logoSoligenix to Present Results from its Ricin Toxin Vaccine Program at the Society of Toxicology 56th Annual Meeting
www.bizjournals.com - March 10 at 8:10 AM
biz.yahoo.com logoSOLIGENIX, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Financial Statements and Exhibits
biz.yahoo.com - March 7 at 4:36 PM
finance.yahoo.com logoSoligenix to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
finance.yahoo.com - February 2 at 7:00 AM
finance.yahoo.com logoTechnical Data and the Price Movement -- Analyst Review of Praxsyn, Baristas Coffee Company, Soligenix and Acacia Diversified Holdings
finance.yahoo.com - February 1 at 9:20 AM
finance.yahoo.com logo7:09 am Soligenix provides 2016 business outlook and preliminary results dates
finance.yahoo.com - January 26 at 7:09 AM
finance.yahoo.com logoSoligenix Provides 2016 Business Outlook
finance.yahoo.com - January 26 at 7:00 AM
finance.yahoo.com logoMarket Influences That Drive Equities Forward - New Research on American Green, Praxsyn, Norsk Hydro and Soligenix
finance.yahoo.com - January 21 at 9:03 AM
biz.yahoo.com logoSOLIGENIX, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - January 7 at 6:07 AM
finance.yahoo.com logoSNGX has been busy in 2015 to advance its clinical programs.
finance.yahoo.com - January 5 at 10:30 AM
finance.yahoo.com logoVista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); Price Target $7.00
finance.yahoo.com - December 18 at 9:00 AM
finance.yahoo.com logoSNGX: Soligenix Reports Positive Preliminary Results from Phase II Study of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
finance.yahoo.com - December 16 at 12:45 PM
finance.yahoo.com logoSNGX: Soligenix Initiates Pivotal Phase III Clinical Trial of SGX301 for CTCL
finance.yahoo.com - December 14 at 9:55 AM

Social

Chart

Soligenix (SNGX) Chart for Friday, August, 18, 2017

This page was last updated on 8/18/2017 by MarketBeat.com Staff